Immuneering Employee Directory

Immuneering corporate office is located in 245 Main St PMB 2, Cambridge, Massachusetts, 02142, United States and has 51-200 employees.

Employees by Department

Departments

Number of employees

Engineering & Technical

11

Medical & Health

8

Finance

6

Operations

5

C-Suite

4

Legal

3

Marketing

1

Immuneering CEO

BZ
United States flag for contact location.
Benjamin ZeskindCo-Founder & Chief Executive Officer
PhonePhoneEmailEmail
See Profile

Key Employees of Immuneering

Immuneering Global Presence

globalPresence illustration
North America11-50
Europe1-10

Index of contact profiles from Immuneering

Hundreds of professionals searching for Immuneering have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
123

Former Employees at Immuneering

Explore people who held key positions, contributed to Immuneering's success, and advanced their careers.

People from Similar Companies in the Business Services Industry Located in Massachusetts, United States

Frequently Asked Questions Regarding Immuneering Employees

How many employees does Immuneering have?
Immuneering has 51-200 employees
Who is the CEO of Immuneering?
Immuneering’s CEO is Benjamin Zeskind
Who is the CFO of Immuneering?
Immuneering’s CFO is Andrew Gengos
Who are Immuneering key employees?
Some of Immuneering key employees are Andrew Gengos, Michael Bookman, Leah Neufeld, Igor Matushansky
Where is Immuneering located?
Immuneering’s headquarters are located at 245 Main St PMB 2, Cambridge, Massachusetts, 02142, United States
How do I contact Immuneering?
Immuneering Contact Info: Phone number: (617) 500-8080 Website: www.immuneering.com
What does Immuneering do?

Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneerings lead product candidate, IMM-1-... 104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The companys development pipeline also includes several early-stage programs.Read More

Is Immuneering a public company?
Yes, Immuneering is a public company and is traded under the symbol IMRX
See more information about Immuneering Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.